KLDO News and Press, Kaleido Biosciences Inc. From 02/03/21

Kaleido Biosciences (KLDO) announced that it intends to sell $50M of shares in an underwritten public offering.The company also intends to grant the underwriters a 30-day option to purchase an additional $7.5M of shares.Kaleido plans to use proceeds from the offering to fund its continue...

Gainers: New Concept Energy (GBR) +238%.Gran Tierra Energy (GTE) +78%.JanOne (JAN) +65%.Lianluo Smart (LLIT) +58%.The9 (NCTY) +40%.Chicago Rivet & Machine (CVR) +38%.Kaleido Biosciences (KLDO) +34%.Monopar Therapeutics (MNPR) +31%.HyreCar (HYRE) +28%.U.S...

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” confer...

Kaleido Biosciences (KLDO) +2% in premarket has announced interim data from K031 non-IND controlled clinical study evaluating Microbiome Metabolic Therapy ((MMT)) candidate KB109 plus Supportive Self Care ((SSC)) in patients with mild to moderate COVID-19 disease.Prel...

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expecte...

LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. EST on Thursday, Jan. 14, 2021. A live audio webca...

Kaleido Biosciences ([[KLDO]] +4.0%) has completed enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy ((MMT)) candidate KB109 for the treatment of mild-to-moderate COVID-19.The multi-center, non-IND clinical study is designed to ...

LEXINGTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to...

LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3,...

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 - LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quart...